Risk factors for liver rejection: evidence to suggest enhanced allograft tolerance in infancy
- PMID: 9014603
- PMCID: PMC1511799
- DOI: 10.1136/adc.75.6.502
Risk factors for liver rejection: evidence to suggest enhanced allograft tolerance in infancy
Abstract
After liver transplantation, a relatively low intensity immunosuppressive regimen is employed in our unit: after initial triple therapy (prednisolone, azathioprine, cyclosporin), prednisolone is discontinued at three months and azathioprine at one year. A retrospective study was therefore performed to determine the incidence of rejection, and to identify risk factors for rejection in our patient population. Over a 10 year period, 135 transplants were performed on 109 children. Thirty four (25%) were on infants less than 1 year old. Incidences of acute rejection and irreversible chronic rejection were calculated for grafts surviving more than one and four weeks respectively. Acute rejection occurred in 51 of 101 allografts (50%), and irreversible chronic rejection in 11 of 91 allografts (12%). The immunosuppression strategy was not associated with an increased incidence of rejection. Acute rejection occurred in only eight of 28 allografts (29%) in those transplanted during their first year, compared with 43 of 73 (59%) in older children. Logistic and Cox regression analysis supported age at transplantation as a significant risk factor for acute rejection. Irreversible chronic rejection did not occur in any of 24 grafts in patients transplanted before one year, compared with 11 of 67 (16%) in older recipients. This suggests possible enhanced allograft tolerance with transplantation during the first year of life. This unexpected and potentially important finding now requires confirmation in other large patient series, with blind interpretation of post-transplant liver biopsies.
Similar articles
-
Significance of central perivenulitis in pediatric liver transplantation.Am J Surg Pathol. 2008 Oct;32(10):1479-88. doi: 10.1097/PAS.0b013e31817a8e96. Am J Surg Pathol. 2008. PMID: 18708942
-
Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants.JAMA. 2012 Jan 18;307(3):283-93. doi: 10.1001/jama.2011.2014. JAMA. 2012. PMID: 22253395
-
Results of transplantation for acute and chronic hepatic allograft rejection.J Pediatr Surg. 1998 Jun;33(6):909-12. doi: 10.1016/s0022-3468(98)90672-8. J Pediatr Surg. 1998. PMID: 9660227
-
Tacrolimus: a further update of its use in the management of organ transplantation.Drugs. 2003;63(12):1247-97. doi: 10.2165/00003495-200363120-00006. Drugs. 2003. PMID: 12790696 Review.
-
Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration.Transpl Int. 2016 Jun;29(6):655-62. doi: 10.1111/tri.12652. Epub 2015 Sep 14. Transpl Int. 2016. PMID: 26265179 Free PMC article. Review.
Cited by
-
Transplant Tolerance Induction: Insights From the Liver.Front Immunol. 2020 Jun 5;11:1044. doi: 10.3389/fimmu.2020.01044. eCollection 2020. Front Immunol. 2020. PMID: 32582167 Free PMC article. Review.
-
Long-term results of pediatric liver transplantation in a combined pediatric and adult transplant program.CMAJ. 2002 Jun 25;166(13):1663-71. CMAJ. 2002. PMID: 12126320 Free PMC article.
-
Strategies for optimizing immunosuppression in adolescent transplant recipients: a focus on liver transplantation.Paediatr Drugs. 2003;5(3):177-83. doi: 10.2165/00128072-200305030-00004. Paediatr Drugs. 2003. PMID: 12608882 Review.
-
Current status of liver transplantation.Indian J Pediatr. 2003 Sep;70(9):731-6. doi: 10.1007/BF02724316. Indian J Pediatr. 2003. PMID: 14620189
-
Immunosuppressive drugs in paediatric liver transplantation.Paediatr Drugs. 2001;3(1):43-60. doi: 10.2165/00128072-200103010-00004. Paediatr Drugs. 2001. PMID: 11220404 Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical